MDH1
Malate dehydrogenase, cytoplasmic
Also known as: MDHC_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P40925
- Gene
- MDH1
- Ensembl
- ENSG00000014641
- Chromosome
- 2
- Canonical length
- 334 aa
- Protein class
- Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Centrosome,Cytosol
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes an enzyme that catalyzes the NAD/NADH-dependent, reversible oxidation of malate to oxaloacetate in many metabolic pathways, including the citric acid cycle. Two main isozymes are known to exist in eukaryotic cells: one is found in the mitochondrial matrix and the other in the cytoplasm. This gene encodes the cytosolic isozyme, which plays a key role in the malate-aspartate shuttle that allows malate to pass through the mitochondrial membrane to be transformed into oxaloacetate for further cellular processes. Alternatively spliced transcript variants have been found for this gene. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is localized in the peroxisomes. Pseudogenes have been identified on chromosomes X and 6. [provided by RefSeq, Feb 2016]
Canonical amino-acid sequenceUniProt
334 residues, UniProt reviewed canonical sequence.
>P40925|MDH1
1 MSEPIRVLVT GAAGQIAYSL LYSIGNGSVF GKDQPIILVL LDITPMMGVL DGVLMELQDC
61 ALPLLKDVIA TDKEDVAFKD LDVAILVGSM PRREGMERKD LLKANVKIFK SQGAALDKYA
121 KKSVKVIVVG NPANTNCLTA SKSAPSIPKE NFSCLTRLDH NRAKAQIALK LGVTANDVKN
181 VIIWGNHSST QYPDVNHAKV KLQGKEVGVY EALKDDSWLK GEFVTTVQQR GAAVIKARKL
241 SSAMSAAKAI CDHVRDIWFG TPEGEFVSMG VISDGNSYGV PDDLLYSFPV VIKNKTWKFV
301 EGLPINDFSR EKMDLTAKEL TEEKESAFEF LSSALocalizationUniProt · AlphaFold · HPA
Whether an antibody against MDH1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.24
- Highest tissue expression
- 1,722 nTPM
Expression across tissuesHPA
Tissue
- tongue: 1,722 nTPM
- heart muscle: 1,262 nTPM
- skeletal muscle: 742 nTPM
- cerebral cortex: 561 nTPM
- parathyroid gland: 386 nTPM
- basal ganglia: 381 nTPM
Single-cell type
- parietal cells: 1,031 nCPM
- hofbauer cells: 596 nCPM
- oocytes: 318 nCPM
- extravillous trophoblasts: 306 nCPM
- migrating cytotrophoblasts: 301 nCPM
- cardiomyocytes: 291 nCPM
Immune cell
- T-reg: 322 nTPM
- total PBMC: 321 nTPM
- basophil: 272 nTPM
- intermediate monocyte: 268 nTPM
- naive B-cell: 260 nTPM
- memory B-cell: 260 nTPM
Brain region
- cerebral cortex: 454 nTPM
- hypothalamus: 325 nTPM
- thalamus: 316 nTPM
- pons: 305 nTPM
- medulla oblongata: 299 nTPM
- cerebellum: 291 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about MDH1.
Disease | AllUniProt
Conditions MDH1 is implicated in, by any mechanism.
- Developmental and epileptic encephalopathy 88 (DEE88) MIM:618959
Disease | GeneticClinVar
1 pathogenic / likely-pathogenic of 58 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Developmental and epileptic encephalopathy, 88
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.37
- gnomAD pLI
- 0.93
- gnomAD missense Z
- 1.18
- DepMap mean gene effect
- -0.02
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- malate metabolic process
- malate-aspartate shuttle
- NAD+ metabolic process
- NADP+ metabolic process
- oxaloacetate metabolic process
- tricarboxylic acid cycle
Molecular functions
- L-malate dehydrogenase (NAD+) activity
- malic enzyme activity
- (2R)-hydroxyphenylpyruvate reductase [NAD(P)H] activity
- diiodophenylpyruvate reductase (NAD+) activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Lactate/malate dehydrogenase, N-terminal
- Malate dehydrogenase, active site
- L-lactate/malate dehydrogenase
- Malate dehydrogenase, type 2
- Lactate dehydrogenase/glycoside hydrolase, family 4, C-terminal
- Lactate/malate dehydrogenase, C-terminal
- NAD(P)-binding domain superfamily
- lactate/malate dehydrogenase, NAD binding domain
- lactate/malate dehydrogenase, alpha/beta C-terminal domain
- Malate dehydrogenase, NAD-dependent, cytosolic
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MDH1 as an antibody target. Whether an autoantibody or antibody against MDH1 could matter depends on whether native MDH1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MDH1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label MDH1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...